UroGen Pharma’s (URGN) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of UroGen Pharma (NASDAQ:URGN) in a research report report published on Thursday, MarketBeat reports. The brokerage currently has a $54.00 price objective on the stock.

Separately, Oppenheimer reduced their price objective on shares of UroGen Pharma from $35.00 to $34.00 and set an outperform rating for the company in a research note on Friday, March 15th.

UroGen Pharma Price Performance

Shares of NASDAQ URGN opened at $14.26 on Thursday. The firm has a fifty day moving average price of $16.30 and a 200-day moving average price of $14.59. The stock has a market cap of $334.40 million, a PE ratio of -3.82 and a beta of 1.07. UroGen Pharma has a 1 year low of $8.69 and a 1 year high of $24.13.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.05). The firm had revenue of $23.53 million for the quarter, compared to analysts’ expectations of $22.30 million. On average, research analysts expect that UroGen Pharma will post -3.59 EPS for the current year.

Insider Activity at UroGen Pharma

In related news, insider Mark Schoenberg sold 3,789 shares of the firm’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $15.74, for a total transaction of $59,638.86. Following the completion of the transaction, the insider now directly owns 149,423 shares of the company’s stock, valued at $2,351,918.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, insider Mark Schoenberg sold 3,789 shares of the firm’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $15.74, for a total transaction of $59,638.86. Following the completion of the transaction, the insider now directly owns 149,423 shares of the company’s stock, valued at $2,351,918.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Jason Drew Smith sold 4,993 shares of the firm’s stock in a transaction on Wednesday, January 31st. The shares were sold at an average price of $15.74, for a total transaction of $78,589.82. Following the transaction, the general counsel now directly owns 18,824 shares of the company’s stock, valued at $296,289.76. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 20,782 shares of company stock valued at $306,829. Corporate insiders own 11.13% of the company’s stock.

Hedge Funds Weigh In On UroGen Pharma

Several institutional investors have recently bought and sold shares of the stock. Lazard Asset Management LLC bought a new position in UroGen Pharma during the fourth quarter valued at $27,000. Acadian Asset Management LLC bought a new position in UroGen Pharma during the first quarter valued at $42,000. Legal & General Group Plc lifted its position in UroGen Pharma by 34.6% during the fourth quarter. Legal & General Group Plc now owns 2,868 shares of the company’s stock valued at $43,000 after purchasing an additional 738 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in UroGen Pharma during the third quarter valued at $53,000. Finally, BNP Paribas Arbitrage SNC lifted its position in UroGen Pharma by 2,782.5% during the second quarter. BNP Paribas Arbitrage SNC now owns 5,102 shares of the company’s stock valued at $53,000 after purchasing an additional 4,925 shares during the last quarter. 91.29% of the stock is owned by hedge funds and other institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.